Tilray Brands, Inc 8-K, filed May 11, 2020
Tilray Brands, Inc. (TLRY)
About this 8-K
Tilray Brands, Inc filed this 8-K on May 11, 2020.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 11, 2020, Tilray, Inc. (“Tilray”) issued a press release announcing financial results for its first quarter ended March 31, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this current report on Form 8-K, including the press release attached as Exhibit 99.1 hereto, is being furnished, but shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Tilray, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Company Name |
|
|
|
|
|
|
|
Date: May 11, 2020 |
|
By: |
/s/ Brendan Kennedy |
|
|
|
|
Brendan Kennedy |
|
|
|
|
President and Chief Executive Officer |
2
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
Tilray, Inc. Reports First Quarter 2020 Financial Results
Quarterly Revenue Increased 126% to $52.1 Million (C$70.7 Million) Compared to the First Quarter of 2019 and 11% Sequentially from the Fourth Quarter of 2019
International Medical Cannabis Sales Exceeded Canada Medical Sales by 43% in the Quarter
Implemented Cost Reductions Designed to Achieve Approximately $40 Million Annualized Savings
Reduced Net Loss by $35 Million, or 16%, Compared to the Fourth Quarter of 2019
Implemented COVID-19 Related Protocols to Ensure the Health of Our Global Workforce and Satisfy Patient and Consumer Needs
Focused on Achieving Positive Adjusted EBITDA by End of the Fourth Quarter of 2020
NANAIMO, BRITISH COLUMBIA – Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the first quarter ended March 31, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“We are pleased to report strong sequential quarterly revenue growth across each of our core business segments for the first quarter of 2020,” says Brendan Kennedy, Tilray’s Chief Executive Officer. “We remain focused on executing on our long-term growth opportunities and our goal of generating positive Adjusted EBITDA by the end of the fourth quarter. As evidenced by our International Medical sales in the quarter, we expect this segment to demonstrate continued growth and positively impact margins. During and since the first quarter, we took significant steps to drive efficiencies across our business, enabling us to realize annualized cost savings of approximately $40 million compared to fourth quarter 2019 run rates. While the positive impact of these actions are not fully reflected in this quarter’s results, they will become more clearly evident over the course of this year.”
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
First Quarter 2020 Financial Highlights
|
|
• |
Revenue increased 126.2% to $52.1 million (C$70.7 million), compared to the first quarter of last year. Growth was driven by cannabis sales, which experienced meaningful increases across all channels with the exception of bulk, and the inclusion of the Manitoba Harvest acquisition for a full quarter in 2020 compared to a partial quarter in the prior year. |
|
|
• |
Revenue increased 11.0% compared to the fourth quarter of 2019. Growth was driven by a 23.0% increase in adult-use sales and a 14.3% increase in hemp product sales, partially offset by a decline in bulk sales. |
(in thousands of United States dollars)
|
|
|
Three months ended March 31, |
|
|||||||||||||
|
|
2020 |
|
|
2019 |
|
|
$ Change |
|
|
% Change |
|
|||||
|
Cannabis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adult-use |
|
$ |
20,919 |
|
|
$ |
7,880 |
|
|
$ |
13,039 |
|
|
|
165 |
% |
|
Canada - medical |
|
|
4,051 |
|
|
|
2,998 |
|
|
|
1,053 |
|
|
|
35 |
% |
|
International - medical |
|
|
5,806 |
|
|
|
1,811 |
|
|
|
3,995 |
|
|
|
221 |
% |
|
Bulk |
|
|
— |
|
|
|
4,767 |
|
|
|
(4,767 |
) |
|
|
(100 |
)% |
|
Total Cannabis revenue |
|
|
30,776 |
|
|
|
17,456 |
|
|
|
13,320 |
|
|
|
76 |
% |
|
Hemp |
|
|
21,326 |
|
|
|
5,582 |
|
|
|
15,744 |
|
|
|
282 |
% |
|
Total |
|
$ |
52,102 |
|
|
$ |
23,038 |
|
|
$ |
29,064 |
|
|
|
126 |
% |
|
Excise duties included in revenue |
|
$ |
4,972 |
|
|
$ |
1,559 |
|
|
$ |
3,413 |
|
|
|
219 |
% |
|
|
• |
Total cannabis kilogram equivalents sold increased 92.4% to 5,794 kilograms from 3,012 kilograms in the first quarter of 2019. This growth resulted from increases in adult-use cannabis flower sales and the launch of Cannabis 2.0 products. |
|
|
• |
Gross margin for the quarter was 21%, a 200 basis point decrease compared to the first quarter of 2019 and a significant positive change over the negative margins recorded in the fourth quarter of 2019. Gross margin, excluding inventory valuation adjustments, increased to 29% from 28% compared to the first quarter of 2019 and 24% in the fourth quarter of 2019. Gross margin for cannabis, excluding inventory valuation adjustments, decreased to 20% from 23% compared to the first quarter of 2019 while gross margin for hemp, excluding inventory valuation adjustments, decreased to 41% from 44% compared to the first quarter of 2019. |
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
|
|
• |
Net loss was reduced by $35.0 million, or 16%, compared to the fourth quarter of 2019. The reduction in net loss from $219.1 million, or $2.14 per share, in the fourth quarter of 2019 was largely due to improvements in gross margin in the first quarter of 2020 and the significant impairments recorded in the fourth quarter of 2019. |
|
|
• |
Adjusted EBITDA was a loss of $19.7 million compared to a loss of $15.3 million in the first quarter of 2019. The moderate increase in Adjusted EBITDA loss was largely the result of increased costs in general and administrative expenses related to commercial growth initiatives and increased operating costs related to our cultivation efforts. |
|
|
• |
Adjusted EBITDA loss of $19.7 million was a 44% improvement over the $35.3 loss during fourth quarter of 2019. The improvement was generally due to cost reductions and operating efficiencies. |
|
|
• |
The Company ended the first quarter of 2020 with $174.0 million in cash. |
First Quarter 2020 Business Highlights
|
|
• |
Tilray made several additions to its executive leadership team: |
|
|
o |
Jon Levin, formerly of Revlon, joined the Company as Chief Operating Officer. |
|
|
o |
Michael Kruteck, formerly of Molson Coors and Pharmaca, joined the Company as Chief Financial Officer. |
|
|
• |
In January 2020, the Company signed a 2.5 tonne strategic partnership agreement with Canndoc (an Israeli Medical Cannabis Agency) to export medical cannabis from Tilray’s European Union facility in Portugal to Israel. The successful export addresses growing demand for medical cannabis products in the Israeli market. |
|
|
• |
On February 28, 2020, the Company closed a $59.6 million senior credit facility that bears interest at Canadian prime plus 8% and has a two year term. |
|
|
• |
On March 17, 2020, the Company closed an underwritten registered offering of common stock, pre-funded warrants and warrants. Net proceeds from this offering were approximately $85.3 million after deducting underwriting discounts and offering expenses. |
|
|
• |
On March 25, 2020, Tilray’s Board of Directors unanimously approved the pro rata release of 11 million shares of Class 2 common stock held by the former stockholders of Privateer Holdings, Inc. The released shares are part of the previously announced release of Tilray stock over a two-year period. |
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
During the COVID-19 pandemic, the Company’s priority remains the health, safety and well-being of its global workforce, patients, customers and communities where it operates. Over the course of several weeks, the Company enacted response protocols and contingency plans to prepare for events in relation to the global pandemic. The Company has implemented remote work arrangements for all office personnel and restricted business travel as of mid-March. The Company’s operational sites remain open, but with enhanced measures to protect the safety of its workforce including rotating shifts of self-quarantined staff, reducing the sites to business-critical personnel only, physical distancing incorporated into manufacturing lines and cultivations sites, sanitation protocols and other enhanced safety measures. These protocols are being evaluated and adapted in accordance with government and health authority recommendations on a daily basis.
Currently, the Company is focused on establishing a safe recovery plan for returning to more normal business conditions and returning staff to corporate offices and operational sites when appropriate.
To date, the Company has not experienced any material COVID-19 impacts related to its ability to serve patients and consumers around the world with medical cannabis products, adult-use cannabis products in Canada, and Manitoba Harvest hemp products. For more information on COVID-19 and associated risks to our business, see Item 1A, “Risk Factors” in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 11, 2020.
Conference Call
The Company will host a conference call today, May 11, 2020, to discuss these results at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Tuesday, May 26, 2020, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international locations, and entering confirmation code 7890876.
There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived for 30 days.
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
About Tilray®
Tilray (Nasdaq: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 15 countries spanning five continents.
Forward Looking Statements
This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements regarding our growth potential, the sustainability of growth, our ability to become Adjusted EBITDA positive, demand for our products and the medical and adult-use cannabis markets, anticipated plans for strategic partnerships and acquisitions, and future sales of our common stock. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 11, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA and Gross margin, excluding inventory valuation adjustments, which are financial measures which are not calculated in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).
Adjusted EBITDA is calculated as net income(loss) before inventory valuation adjustments; interest expenses, net; other expenses (income), net; deferred income tax (recoveries) expenses, current income tax expenses (benefit); foreign exchange gain (loss), net; depreciation and amortization expenses; stock-based compensation expenses; other stock-based compensation related expenses; loss from equity method investments; finance income from ABG; loss on disposal of property and equipment; acquisition-related (income) expense; amortization of inventory step-up;
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
severance costs; impairment of assets; and change in fair value of warrant liability. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.
The Company believes these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses these non-GAAP financial measures to compare the Company's performance to that of prior periods for trend analyses and planning purposes. These non-GAAP financial measures are also presented to the Company’s Board of Directors.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company's financial statements and are subject to inherent limitations.
For further information:
Media: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
TILRAY, INC.
Condensed Consolidated Statements of Net Loss and Comprehensive Loss
(in thousands of United States dollars, except for share and per share data, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
||||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Revenue (inclusive of excise duties of $4,972 and $1,559, respectively) |
|
$ |
52,102 |
|
|
$ |
23,038 |
|
|
Cost of sales |
|
|
|
|
|
|
|
|
|
Product costs |
|
|
37,188 |
|
|
|
17,329 |
|
|
Inventory valuation adjustments |
|
|
4,044 |
|
|
|
324 |
|
|
Gross profit |
|
|
10,870 |
|
|
|
5,385 |
|
|
General and administrative expenses |
|
|
17,776 |
|
|
|
12,934 |
|
|
Sales and marketing expenses |
|
|
17,876 |
|
|
|
7,821 |
|
|
Research and development expenses |
|
|
1,258 |
|
|
|
1,048 |
|
|
Stock-based compensation expenses |
|
|
7,677 |
|
|
|
5,736 |
|
|
Depreciation and amortization expenses |
|
|
3,591 |
|
|
|
1,865 |
|
|
Impairment of assets |
|
|
29,839 |
|
|
|
— |
|
|
Acquisition-related expenses, net |
|
|
2,355 |
|
|
|
4,424 |
|
|
Loss from equity method investments |
|
|
1,748 |
|
|
|
— |
|
|
Operating loss |
|
|
(71,250 |
) |
|
|
(28,443 |
) |
|
Foreign exchange loss, net |
|
|
28,069 |
|
|
|
179 |
|
|
Change in fair value of warrant liability |
|
|
71,978 |
|
|
|
— |
|
|
Interest expenses, net |
|
|
9,146 |
|
|
|
8,744 |
|
|
Finance income from ABG |
|
|
— |
|
|
|
(135 |
) |
|
Other expense (income), net |
|
|
4,651 |
|
|
|
(3,845 |
) |
|
Loss before income taxes |
|
|
(185,094 |
) |
|
|
(33,386 |
) |
|
Deferred income tax recoveries |
|
|
(1,272 |
) |
|
|
(3,777 |
) |
|
Current income tax expenses (benefit) |
|
|
301 |
|
|
|
(240 |
) |
|
Net loss |
|
$ |
(184,123 |
) |
|
$ |
(29,369 |
) |
|
Net loss per share - basic and diluted |
|
|
(1.73 |
) |
|
|
(0.31 |
) |
|
Weighted average shares used in computation of net loss per share - basic and diluted |
|
|
106,463,352 |
|
|
|
94,875,351 |
|
|
Net loss |
|
$ |
(184,123 |
) |
|
$ |
(29,369 |
) |
|
Foreign currency translation loss, net |
|
|
(16,633 |
) |
|
|
(475 |
) |
|
Unrealized (loss) gain on available-for-sale debt securities |
|
|
(74 |
) |
|
|
19 |
|
|
Other comprehensive loss |
|
|
(16,707 |
) |
|
|
(456 |
) |
|
Comprehensive loss |
|
$ |
(200,830 |
) |
|
$ |
(29,825 |
) |
In the fourth quarter of 2019, the Company adopted ASU 2016-01, ASC 842, ASC 606 and ASU 2018-07. The first quarter of 2019 has been recast to reflect the effects of this adoption.
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
Condensed Consolidated Balance Sheets
(in thousands of United States dollars, except for share and par value data, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020 |
|
|
December 31, 2019 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
173,990 |
|
|
$ |
96,791 |
|
|
Accounts receivable, net of allowance for credit losses of $595 and provision for sales returns of $1,138 (December 31, 2019 - $615 and $1,400, respectively) |
|
|
38,324 |
|
|
|
36,202 |
|
|
Inventory |
|
|
95,586 |
|
|
|
87,861 |
|
|
Prepayments and other current assets |
|
|
31,066 |
|
|
|
38,173 |
|
|
Total current assets |
|
|
338,966 |
|
|
|
259,027 |
|
|
Property and equipment, net |
|
|
186,970 |
|
|
|
184,217 |
|
|
Operating lease, right-of-use assets |
|
|
18,654 |
|
|
|
17,514 |
|
|
Intangible assets, net |
|
|
187,892 |
|
|
|
228,828 |
|
|
Goodwill |
|
|
150,870 |
|
|
|
163,251 |
|
|
Equity method investments |
|
|
8,827 |
|
|
|
11,448 |
|
|
Other investments |
|
|
21,250 |
|
|
|
24,184 |
|
|
Other assets |
|
|
2,135 |
|
|
|
7,861 |
|
|
Total assets |
|
$ |
915,564 |
|
|
$ |
896,330 |
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
|
23,907 |
|
|
|
39,125 |
|
|
Accrued expenses and other current liabilities |
|
|
47,032 |
|
|
|
50,829 |
|
|
Accrued lease obligations |
|
|
3,370 |
|
|
|
2,473 |
|
|
Senior Facility - current |
|
|
4,723 |
|
|
|
— |
|
|
Warrant liability |
|
|
92,339 |
|
|
|
— |
|
|
Total current liabilities |
|
|
171,371 |
|
|
|
92,427 |
|
|
Accrued lease obligations |
|
|
28,538 |
|
|
|
29,407 |
|
|
Deferred tax liability |
|
|
48,019 |
|
|
|
53,363 |
|
|
Convertible notes, net of issuance costs |
|
|
432,807 |
|
|
|
430,210 |
|
|
Senior Facility, net of transaction costs |
|
|
39,106 |
|
|
|
— |
|
|
Other liabilities |
|
|
5,415 |
|
|
|
5,652 |
|
|
Total liabilities |
|
$ |
725,256 |
|
|
$ |
611,059 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
|
Class 1 common stock ($0.0001 par value, 250,000,000 shares authorized; 16,666,665 shares issued and outstanding) |
|
|
2 |
|
|
|
2 |
|
|
Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized; 107,976,818 and 86,114,560 shares issued and outstanding, respectively |
|
|
11 |
|
|
|
9 |
|
|
Additional paid-in capital |
|
|
840,436 |
|
|
|
705,671 |
|
|
Accumulated other comprehensive (loss) income |
|
|
(6,988 |
) |
|
|
9,719 |
|
|
Accumulated deficit |
|
|
(643,153 |
) |
|
|
(430,130 |
) |
|
Total stockholders’ equity |
|
|
190,308 |
|
|
|
285,271 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
915,564 |
|
|
$ |
896,330 |
|
Tilray | www.tilray.com
|
|
Exhibit 99.1 |
|
PRESS RELEASE |
May 11, 2020 |
(in thousands of United States dollars)
|
|
|
Three months ended March 31, |
|
|||||
|
|
2020 |
|
|
2019 |
|
|||
|
Adjusted EBITDA reconciliation: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(184,123 |
) |
|
$ |
(29,369 |
) |
|
Inventory valuation adjustments |
|
|
4,044 |
|
|
|
324 |
|
|
Severance costs |
|
|
1,861 |
|
|
|
— |
|
|
Depreciation and amortization expenses |
|
|
3,591 |
|
|
|
1,865 |
|
|
Stock-based compensation expenses |
|
|
7,677 |
|
|
|
5,736 |
|
|
Impairment of assets |
|
|
29,839 |
|
|
|
— |
|
|
Acquisition-related expenses, net |
|
|
2,355 |
|
|
|
4,424 |
|
|
Loss from equity method investments |
|
|
1,748 |
|
|
|
— |
|
|
Foreign exchange loss, net |
|
|
28,069 |
|
|
|
179 |
|
|
Change in fair value of warrant liability |
|
|
71,978 |
|
|
|
— |
|
|
Interest expenses, net |
|
|
9,146 |
|
|
|
8,744 |
|
|
Finance income from ABG |
|
|
— |
|
|
|
(135 |
) |
|
Loss from disposal of property and equipment |
|
|
457 |
|
|
|
111 |
|
|
Other expense (income), net |
|
|
4,651 |
|
|
|
(3,845 |
) |
|
Amortization of inventory step-up |
|
|
— |
|
|
|
681 |
|
|
Deferred income tax recoveries |
|
|
(1,272 |
) |
|
|
(3,777 |
) |
|
Current income tax expenses (benefit) |
|
|
301 |
|
|
|
(240 |
) |
|
Adjusted EBITDA |
|
$ |
(19,678 |
) |
|
$ |
(15,302 |
) |
(in thousands of United States dollars, except percentages)
|
|
|
Three months ended March 31, |
|
|||||||||||||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
|||||||
|
Gross margin, excluding inventory valuation adjustments reconciliation: |
|
Cannabis |
|
|
Hemp |
|
|
Total |
|
|||||||||||||||
|
Revenue |
|
$ |
30,776 |
|
|
$ |
17,456 |
|
|
$ |
21,326 |
|
|
$ |
5,582 |
|
|
$ |
52,102 |
|
|
$ |
23,038 |
|
|
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product costs |
|
|
24,603 |
|
|
|
13,511 |
|
|
|
12,585 |
|
|
|
3,818 |
|
|
|
37,188 |
|
|
|
17,329 |
|
|
Inventory valuation adjustments |
|
|
3,247 |
|
|
|
324 |
|
|
|
797 |
|
|
|
— |
|
|
|
4,044 |
|
|
|
324 |
|
|
Gross profit |
|
|
2,926 |
|
|
|
3,621 |
|
|
|
7,944 |
|
|
|
1,764 |
|
|
|
10,870 |
|
|
|
5,385 |
|
|
Inventory valuation adjustments |
|
|
3,247 |
|
|
|
324 |
|
|
|
797 |
|
|
|
— |
|
|
|
4,044 |
|
|
|
324 |
|
|
Amortization of inventory step-up |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
681 |
|
|
|
— |
|
|
|
681 |
|
|
Gross profit, excluding inventory valuation adjustments |
|
$ |
6,173 |
|
|
$ |
3,945 |
|
|
$ |
8,741 |
|
|
$ |
2,445 |
|
|
$ |
14,914 |
|
|
$ |
6,390 |
|
|
Gross margin, excluding inventory valuation adjustments |
|
|
20 |
% |
|
|
23 |
% |
|
|
41 |
% |
|
|
44 |
% |
|
|
29 |
% |
|
|
28 |
% |
In the fourth quarter of 2019, the Company adopted ASU 2016-01, ASC 842, ASC 606 and ASU 2018-07. The first quarter of 2019 has been recast to reflect the effects of this adoption.
Tilray | www.tilray.com